15 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
of the product by regulatory authorities;
recall of the product;
restrictions on the marketing of the product or the manufacturing process for any component … manufacture and requiring us to recall or remove the product from the market. The regulators could also suspend or withdraw our marketing authorizations
6-K
EX-99.3
OBSVF
ObsEva SA
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension … an enforcement action against the Company or any of its Significant Subsidiaries that causes the Company or any such Significant Subsidiary to recall
6-K/A
EX-99.2
OBSVF
ObsEva SA
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders … an enforcement action against the Company or any of its Significant Subsidiaries that causes the Company or any such Significant Subsidiary to recall
6-K
EX-99.2
9cx nch5govmiuhs5
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
d7zm4f1u6sqt8y
13 Nov 19
Index to Unaudited Condensed Consolidated Financial Statements
4:00pm
6-K
EX-99.1
v5s lvxn6
7 Aug 19
Current report (foreign)
7:21am
20-F
4r2mrnwx0917uqyioq
21 Apr 17
Annual report (foreign)
12:00am
F-1
4udgops
30 Dec 16
Registration statement (foreign)
12:00am
DRS
rmkb4v7j1v1gzu
14 Oct 16
Draft registration statement
12:00am
- Prev
- 1
- Next